Amongst sufferers with relapsed platinum-sensitive ovarian most cancers, upkeep remedy with Lynparza (olaparbib) plus cediranib didn’t end in vital enhancements to progression-free survival (PFS; the time a affected person lives with out their illness spreading or worsening) or total survival (OS; the time a affected person lives, no matter illness standing) when in comparison with remedy with standalone Lynparza, research findings have proven.
Based on findings from the section 3 ICON9 research introduced on the 2024 ESMO Congress, at a median follow-up of 37 months, the median PFS was 11 months and 13.9 months within the Lynparza and Lynparza/cediranib arms, respectively.
“This was not statistically vital,” chief trial investigator Shibani Nicum, a marketing consultant medical oncologist and affiliate professor of Medical Oncology at College Faculty Hospital London, stated throughout a presentation of the info.
Research Highlights:
- Upkeep remedy with Lynparza plus cediranib didn’t considerably enhance progression-free survival (PFS) or total survival (OS) in comparison with Lynparza alone in sufferers with relapsed platinum-sensitive ovarian most cancers.
- Relating to security, the protection profile was typically in step with anticipated toxicities from the 2 brokers. Occasions occurred in 17.6% (30 of 170 sufferers) and 19.8% (33 of 167 sufferers) from the Lynparza monotherapy and Lynparza/cediranib arms, respectively
ICON9 is a world educational, managed, randomized section 3 trial that assessed the efficacy of Lynparza and cediranib as upkeep remedy in first platinum-sensitive relapsed ovarian most cancers after a previous response to platinum-based remedy.
“By way of background, the vast majority of sufferers who current with superior ovarian most cancers will relapse inside 18 to 24 months,” Nicum stated. “In platinum-sensitive relapse, the PARP inhibitor [Lynparza] and the VEGF inhibitor cediranib have individually led to improved outcomes.”
Sufferers with relapsed platinum-sensitive ovarian, fallopian tube and first peritoneal most cancers have been enrolled within the research (330 sufferers). Key eligibility standards included having platinum-sensitive recurrence, most of two prior traces of remedy, full response or partial response after a minimal of 4 cycles of chemotherapy, BRCA of any type and no prior remedy with PARP inhibitors. Sufferers have been stratified based mostly on tumor BRCA standing, surgical procedure versus no surgical procedure relapse, prior remedy with Avastin (bevacizumab), progression-free interval of six to 12 months versus longer than 12 months and nation.
Based on the outcomes, at a median follow-up of 37 months, the OS within the intention-to-treat inhabitants didn’t have a big distinction by any stratification issue.
Arm 1 included 167 sufferers who have been handled with oral Lynparza at 300 milligrams twice day by day (BD) plus oral cediranib at 20 milligrams as soon as day by day (OD) till illness development or past if medical profit is derived. Arm 2 included 170 sufferers who acquired 300 milligrams of oral Lynparza BD till illness development or if medical profit was derived.
The first finish level was PFS; secondary finish factors included OS, toxicity, adherence, high quality of life (QoL), cost-effectiveness, additional remedy and response fee.
Baseline traits in each remedy arms have been balanced: the median ages have been 64 years and 62 years within the Lynparza monotherapy and Lynparza/cediranib arms, respectively; majority had an ECOG efficiency standing of 0 (wanted no help performing day by day duties , 56.5% versus 61.1%); majority had a serous histological sort of carcinoma (97% versus 97.6%) and the vast majority of sufferers didn’t endure surgical procedure at relapse (85.3% versus 88.6%).
Relating to security, the protection profile was typically in step with anticipated toxicities from the 2 brokers. Occasions occurred in 17.6% (30 of 170 sufferers) and 19.8% (33 of 167 sufferers) from the Lynparza monotherapy and Lynparza/cediranib arms, respectively. Progressive illness occurred in 82.1% (115 sufferers) and 76.9% (103 sufferers) of sufferers within the respective arms; toxicity occurred in 10.7% (15 sufferers) and 13.4% (18 sufferers). The median variety of cycles was eight and 11, respectively.
The most typical grade 3 or (extreme) greater unwanted effects occurring within the Lynparza plus cediranib versus Lynparza solely teams included anemia (low pink blood cell depend, 23 sufferers versus 20 sufferers), hypertension (hypertension, 16 sufferers versus 4 sufferers), diarrhea (16 sufferers versus three sufferers), fatigue (10 sufferers versus 5 sufferers), decreased neutrophil depend (a sort of white blood cell, 10 sufferers versus 4 sufferers) and belly ache (eight sufferers versus 5 sufferers).
“To conclude, the advance in development or total survival with upkeep [Lynparza] and cediranib was not statistically vital in comparison with [Lynparza] alone,” Nicum stated. “However it’s value noting that within the [Lynparza] arm, the progression-free survival was higher than we had anticipated at 11 months in comparison with 8.4 months, and likewise by way of total survival, it was considerably higher than anticipated at 37.8 months fairly than 29.8 months.”
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
